Skip to main content

Table 4 Serum clinical safety markers, part I

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable

T1

T2

T3

Time*group

Time*group*gender

Cholesterol (mg/dL)

 PLA

155 ± 37

154 ± 34

161 ± 32

Time p = 0.07

G*T*Ge p = 0.38

 LD

151 ± 28

150 ± 26

160 ± 28

G*T p= 0.001

 HD

174 ± 33

162 ± 33

160 ± 32

HDL (mg/dL)

 PLA

49 ± 10

51 ± 12

55 ± 12

Time p = 0.08

G*T*Ge p = 0.99

 LD

47 ± 11

50 ± 12

51 ± 12

G*T p = 0.16

 HD

53 ± 16

49 ± 15

52 ± 16

LDL (mg/dL)

 PLA

89.4 ± 28.9

83.4 ± 28.9

87.7 ± 23.9

Time p= 0.001

G*T*Ge p = 0.38

 LD

85.0 ± 19.8

78.9 ± 17.8

86.9 ± 22.2

G*T p= 0.024

 HD

103.0 ± 22.1

89.3 ± 20.5

89.2 ± 19.9

Cholesterol/HDL

 PLA

3.3 ± 0.9

3.1 ± 0.9

3.0 ± 0.8

Time p = 0.19

G*T*Ge p = 0.48

 LD

3.2 ± 0.8

3.0 ± 0.8

3.2 ± 0.9

G*T p = 0.77

 HD

35 ± 0.9

3.3 ± 0.9

3.3 ± 0.9

Triglycerides (mg/dL)

 PLA

67 ± 25

77 ± 31

73 ± 31

Time p = 0.21

G*T*Ge p = 0.73

 LD

80 ± 45

93 ± 50

97 ± 50

G*T p = 0.63

 HD

87 ± 39

92 ± 40

83 ± 36

Glucose (mg/dL)

 PLA

86 ± 8

86 ± 8

86 ± 6

Time p = 0.14

G*T*Ge p = 0.44

 LD

87 ± 7

86 ± 8

90 ± 8

G*T p = 0.55

 HD

84 ± 9

86 ± 9

86 ± 7

  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Symbols: , different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed